Proteostasis Therapeutics is developing novel disease-modifying therapeutics that modulate protein chaperone and proteasomal degradation pathways within the cell to enhance the function and capacity of the protein homeostasis network or Proteostasis Network. Our product candidates correct for imbalances in the Proteostasis Network resulting from the cumulative effects of disease, genetic mutations, environmental factors, and aging and our lead programs are in cystic fibrosis and protein aggregation diseases such as Parkinson's disease.